相关实验视频
Updated: Jun 29, 2025

05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
6.6K
在肥胖的管理中准GLP-2受体
Thorir G Pálsson1, Hannah Gilliam-Vigh1, Benjamin A H Jensen2
1Center for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark.
Peptides
|April 5, 2024
概括
向类似葡萄糖2 (GLP-2) 可能提供新的肥胖治疗方法. GLP-2增强了肠道屏障功能并减少了炎症,可能补充肥胖管理的抑制食欲的疗法.
科学领域:
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
- 代谢疾病 代谢疾病
背景情况:
- 肥胖与肠道屏障功能受损和全身炎症有关.
- 类似葡萄糖2 (GLP-2) 是一种肠道激素,具有肠和肠道屏障增强的特性.
- GLP-2R在胃肠道,肝脏,脂肪组织和中枢神经系统中表达.
研究的目的:
- 审查肥胖中的GLP-2生理学.
- 探索GLP-2受体 (GLP-2R) 激活用于治疗肥胖的药理潜力.
主要方法:
- 关于GLP-2生理学及其在肥胖中的作用的文献综述.
- 在临床前和临床背景下分析GLP-2R药理学.
- 讨论与其他抗肥胖策略结合GLP-2的潜力.
主要成果:
- GLP-2促进肠道粘膜的增殖,改善肠道屏障的功能.
- GLP-2增强了中腔体的血液流动.
- 在肥胖的动物模型中,GLP-2表现出抗炎作用.
结论:
- GLP-2改善肠道屏障的效果可能会解决肥胖的一个核心机制.
- 结合GLP-2R激活与降低食欲的策略,可以为肥胖及其并发症提供一种新的治疗方法.
相关概念视频
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
G Protein-coupled Receptors
11.9K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.9K
Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Regulation of Food Intake
228
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
228
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174

